Blocking agents targeting the PD-1/PD-L1 pathway also disrupt the PI3K/AKT/mTOR pathway, resulting in inhibition of pancreatic cancer growth, progression and metastatic potential, as observed in an orthotopic mouse model of PDAC. This evidence concerns the gene PIK3CA and pancreatic neoplasm.